- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 235/06 - BenzimidazolesHydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
Patent holdings for IPC class C07D 235/06
Total number of patents in this class: 461
10-year publication summary
43
|
29
|
31
|
30
|
22
|
28
|
23
|
26
|
22
|
7
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Array BioPharma Inc. | 503 |
24 |
AstraZeneca AB | 2924 |
14 |
Probiodrug AG | 63 |
10 |
LG Chem, Ltd. | 17581 |
9 |
F. Hoffmann-La Roche AG | 7932 |
6 |
Vivoryon Therapeutics N.V. | 43 |
6 |
Allergan, Inc. | 2361 |
5 |
Agios Pharmaceuticals, Inc | 216 |
5 |
BioAge Labs, Inc. | 40 |
5 |
Biosplice Therapeutics, Inc. | 171 |
5 |
Novartis AG | 10882 |
4 |
Merck Patent GmbH | 5861 |
4 |
Bayer Pharma AG | 1061 |
4 |
Abbvie Inc. | 1803 |
4 |
Mayo Foundation for Medical Education and Research | 3196 |
4 |
Nippon Shinyaku Co., Ltd. | 332 |
4 |
University of Tennessee Research Foundation | 762 |
4 |
The Wistar Institute of Anatomy and Biology | 447 |
4 |
Regenacy Pharmaceuticals, LLC | 26 |
4 |
Tempest Therapeutics, Inc. | 25 |
4 |
Other owners | 332 |